- In a real-world study of patients with multiple myeloma (MM), response was a key driver of treatment discontinuation in earlier lines of therapy, whereas progressive disease-related death was a more common driver of permanent discontinuation in later lines.
- The data show significant discrepancies with the results of a large European study, highlighting the need for validation of such studies.
Why this matters
- Evidence from a European study suggests up to 39% of patients with MM do not receive second-line therapy.
- Study to investigate the cause of treatment discontinuation in real-world practice in 108 patients with MM from a hospital in Barcelona.
- Funding: None disclosed.
- All 108 patients received first-line therapy; 32% of these did not receive second-line therapy.
- Among 73 patients who did receive second-line therapy, 29 did not receive third-line therapy.
- Achievement of response to therapy was the most common cause of first-line treatment discontinuation (31% of discontinuations); discontinuations for this reason decreased with subsequent treatment lines.
- 14% of patients discontinued first-line therapy because of progressive disease-related death; discontinuations for this reason increased with subsequent treatment lines.
- Retrospective data.